Profile photo Nadia Haj Mohammad

Nadia Haj Mohammad

Assistant Professor - medical

Strategic program(s):

Biography

Dr. N. Haj Mohammad (1976) has been working as a medical oncologist in the UMC Utrecht since 2014. She studied pharmacy in the same city, and completed her pharmacy training in 2001. One year earlier, she started Medical school at the University of Amsterdam. She combined her training as a medical-oncologist at the AMC with PhD research in the clinical outcomes of treatments for gastroesophageal and pancreatic carcinoma.

She is member of the national guidelines for hepatocellular carcinoma and bile duct carcinoma. She is a board member of the Dutch Upper GI Cancer group.

Her research focuses on clinical outcomes of gastroesophageal and primary liver cancers. She is national PI of the phase 2 LyRICX study in metastatic gastroesophageal cancer and is local PI of multiple investigator and sponsor investigated studies within tumors of the upper digestive tract and primary liver tumors.

Strategic program(s):

Contact

Research groups

Primary Liver Tumors research group

Research aim

To improve surveillance, diagnostics, treatment, and outcome for patients with primary liver tumors (hepatocellular carcinoma and cholangiocarcinoma) by interdisciplinary and (inter-)national collaborative research

Go to group

Recent publications

Quality of Life Among Patients With Locally Advanced Pancreatic Cancer Leonard W F Seelen, Simone Augustinus, Thomas F Stoop, Stefan A W Bouwense, Olivier R Busch, Geert A Cirkel, Casper H J van Eijck, Judith de Vos-Geelen, Bas Groot Koerkamp, Nadia Haj Mohammad, Ignace H J T de Hingh, Evelien van Alphen, Marjolein Y V Homs, Mike S L Liem, Maartje Los, Vincent E de Meijer, Leonie J M Mekenkamp, Mirjam A G Sprangers, Martijn W J Stommel, Johanna W Wilmink, Marc G Besselink, Hjalmar C van Santvoort, Hanneke W M van Laarhoven, I Quintus Molenaar,
Journal of the national comprehensive cancer network, 2025, vol. 23, p.97-104
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer Denice Kamp, Anne M. May, Antoine Adenis, Andreia Capela, Sarah Derks, Francesca De Felice, Nina Fokter Dovnik, Cinta Hierro, Aysegul Ilhan-Mutlu, Florian Lordick, Radka Lordick Obermannova, Angelica Petrillo, Alberto Puccini, Ana Raimundo, Giandomenico Roviello, Alexander Siebenhüner, Marije Slingerland, Elizabeth C. Smyth, Hanneke W.M. van Laarhoven, Nadia Haj Mohammad
European Journal of Cancer, 2025, vol. 218
Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma Hanneke van Laarhoven, Rob Verhoeven, Mark van Berge Henegouwen, Nadia Haj Mohammad, Richard van Hillegersberg, Marije Slingerland, Christina T. Muijs, Bas Wijnhoven, Bianca Mostert, Laurens Beerepoot, Grard Nieuwenhuijzen, Sarah Derks, Peter S.N. van Rossum
EClinicalMedicine, 2025, vol. 80
Impaired liver function Marieke Schmidt, Robin Vernooij, Merel van Nuland, Erin Smeijsters, Lot Devriese, Nadia Haj Mohammad, Thom Hermens, Julian Stammers, Christina Swart, Toine Egberts, Saskia Haitjema, Laureen Lammers
BMC Cancer, 2024, vol. 24
Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma Charlotte I Stroes, Sybren L Meijer, Geert-Jan Creemers, Gerrit K J Hooijer, Nadia Haj Mohammad, Maartje Los, Marije Slingerland, Geke A P Hospers, Annemieke Cats, Laurens V Beerepoot, Maarten F Bijlsma, Hanneke W M van Laarhoven
Translational Oncology, 2024, vol. 49
Evaluation of treatment strategies and survival of patients with cT4bM0 esophageal cancer Jingpu Wang, Eline M de Groot, Zhouqiao Wu, Rob H A Verhoeven, Nadia Haj Mohammad, Stella Mook, Lucas Goense, Sheraz R Markar, Jelle P Ruurda, Richard van Hillegersberg
Digestive Surgery, 2024, vol. 41, p.171-180